KG&L Capital Management LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

KG&L Capital Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 30.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,660 shares of the biopharmaceutical company’s stock after selling 16,945 shares during the period. KG&L Capital Management LLC’s holdings in Pfizer were worth $1,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $31,000. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Pfizer by 60.3% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 583,600 shares of the biopharmaceutical company’s stock valued at $16,329,000 after buying an additional 219,600 shares during the period. Central Pacific Bank Trust Division lifted its position in Pfizer by 71.8% in the third quarter. Central Pacific Bank Trust Division now owns 9,286 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 3,880 shares during the last quarter. Czech National Bank boosted its stake in Pfizer by 6.9% during the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after buying an additional 74,737 shares during the period. Finally, Canandaigua National Bank & Trust Co. increased its position in Pfizer by 23.6% during the third quarter. Canandaigua National Bank & Trust Co. now owns 235,277 shares of the biopharmaceutical company’s stock valued at $6,809,000 after acquiring an additional 44,957 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Down 1.5 %

NYSE:PFE opened at $26.51 on Friday. The company’s 50-day simple moving average is $26.27 and its 200-day simple moving average is $27.87. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market capitalization of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the company earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.49%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is currently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.